Simsen Diagnostics

Simsen Diagnostics is a Stockholm-based diagnostics company developing and commercializing a highly sensitive, tumor-informed ctDNA sequencing platform called Simsen® Personal. The company operates as a service provider, offering tailored assay design, analysis, and interpretation to support clinical trials for pharma partners and personalized monitoring for cancer clinics. By focusing on ultra-sensitive detection (down to 0.001% variant allele frequency), Simsen aims to improve early cancer detection, MRD monitoring, and drug development efficiency, positioning itself at the intersection of precision diagnostics and liquid biopsy.

Simsen® Personal - an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) analysis platform. It involves sequencing a patient's tumor to design a personalized assay for tracking specific mutations in blood, with sensitivity down to 0.001% variant allele frequency (VAF).

Simsen operates in the highly competitive field of liquid biopsy and MRD detection. Key competitors include large public companies like Natera (Signatera), Guardant Health (Guardant Reveal), and Personalis (NeXT Personal), as well as private firms like Foresight Diagnostics and ArcherDX. Differentiation is based on sensitivity, specificity, turnaround time, cost, and the breadth of service offerings.